These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 14221711)

  • 1. [CLINICAL OBSERVATIONS ON A NEW DRUG WITH VASOPRESSOR ACTION IN THE TREATMENT OF SHOCK: LEVO-1 (M-HYDROXYPHENYL) -2-AMINO-1-PROPANOL (METARAMINOL)].
    HENRIQUET F; DELEONARDIS A
    Arch Ostet Ginecol; 1964; 69():259-69. PubMed ID: 14221711
    [No Abstract]   [Full Text] [Related]  

  • 2. [NEW METHOD OF SYNTHESIS OF 1-(M-HYDROXYPHENYL)-2-AMINO-1-PROPANOL].
    PESSINA R; BOTTO A; GATTI F; VALENTI G
    Farmaco Sci; 1965 Feb; 20():97-105. PubMed ID: 14300122
    [No Abstract]   [Full Text] [Related]  

  • 3. HEMODYNAMIC EFFECTS OF PRESSOR AGENTS IN SEPTIC AND MYOCARDIAL INFARCTION SHOCK.
    SMULYAN H; CUDDY RP; EICH RH
    JAMA; 1964 Oct; 190():188-94. PubMed ID: 14246588
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical studies on a vasopressor agent: metaraminol (aramine). II. Observations on its use in the management of shock.
    WEIL MH
    Am J Med Sci; 1955 Oct; 230(4):357-69. PubMed ID: 13258566
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical studies on vasopressor agent: metaraminol (aramine). III. Observations on its oral use in the treatment of hypotension.
    WEIL MH
    Am J Med Sci; 1957 Apr; 233(4):367-74. PubMed ID: 13410911
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of shock with sympathicomimetic drugs. Use of metaraminol and comparison with other vasopressor agents.
    MILLS LC; VOUDOUKIS IJ; MOYER JH; HEIDER C
    Arch Intern Med; 1960 Dec; 106():816-23. PubMed ID: 13770952
    [No Abstract]   [Full Text] [Related]  

  • 7. PHARMACOLOGIC APPROACH TO THE TREATMENT OF SHOCK.
    AVIADO DM
    Ann Intern Med; 1965 May; 62():1050-9. PubMed ID: 14283384
    [No Abstract]   [Full Text] [Related]  

  • 8. Vasopressor agents; influence of acidosis on cardiac and vascular responsiveness.
    WEIL MH; HOULE DB; BROWN EB; CAMPBELL GS; HEATH C
    Calif Med; 1958 Jun; 88(6):437-40. PubMed ID: 13536861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [TREATMENT OF ARRHYTHMIA WITH VASOPRESSOR DRUGS].
    FERNANDEZBARBIERI F; CORDAY E; LANG TW
    Arch Inst Cardiol Mex; 1964; 34():395-401. PubMed ID: 14188141
    [No Abstract]   [Full Text] [Related]  

  • 10. Ventricular function. V. The circulatory effects of aramine; mechanism of action of vasopressor drugs in cardiogenic shock.
    SARNOFF SJ; CASE RB; BERGLUND E; SARNOFF LC
    Circulation; 1954 Jul; 10(1):84-93. PubMed ID: 13172865
    [No Abstract]   [Full Text] [Related]  

  • 11. VASOPRESSOR INDUCED MALARIAL RELAPSE AS A COMPLICATION OF ACUTE MYOCARDIAL INFARCTION: REPORT OF A CASE.
    DAVIS JW
    Angiology; 1964 Jun; 15():251-2. PubMed ID: 14170580
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical experiences with metaraminol as a vasopressor agent in spinal anesthesia.
    MUNCHOW OB; GRANATELLI AF; COLLINS VJ; ROVENSTINE EA
    Anesthesiology; 1960; 21():471-5. PubMed ID: 14425226
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical studies on a vasopressor agent: metaraminol (aramine). I. Observations in normotensive subjects.
    WEIL MH; SPINK WW
    Am J Med Sci; 1955 Jun; 229(6):661-9. PubMed ID: 14376394
    [No Abstract]   [Full Text] [Related]  

  • 14. [CLINICAL AND STATISTICAL STUDY OF THE VASOPRESSIVE PROPERTIES OF METARAMINOL WITH 100 HYPOTENSIVE PATIENTS].
    YERNAUX S; GOBIN P
    Brux Med; 1964 Dec; 44():1369-82. PubMed ID: 14245221
    [No Abstract]   [Full Text] [Related]  

  • 15. Norepinephrine and metaraminol in septic shock: a comparison of the hemodynamic effects.
    Natalini G; Schivalocchi V; Rosano A; Taranto M; Pletti C; Bernardini A
    Intensive Care Med; 2005 May; 31(5):634-7. PubMed ID: 15803299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EFFECTS OF VASOPRESSORS AND BLOCKING AGENTS ON THE KIDNEY IN OLIGEMIA.
    GIOJUBS RW; SIMEONE FA
    Surg Forum; 1964; 15():12-3. PubMed ID: 14189284
    [No Abstract]   [Full Text] [Related]  

  • 17. Studies in clinical shock and hypotension. 3. Comparative effects of vasopressor drugs and dextran.
    Cohn JN; Luria MH
    Arch Intern Med; 1965 Oct; 116(4):562-6. PubMed ID: 4284276
    [No Abstract]   [Full Text] [Related]  

  • 18. Vasopressor agents in shock.
    Moyer JH; Mills LC
    Am J Nurs; 1975 Apr; 75(4):620-5. PubMed ID: 1039254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of Metaraminol as a Vasopressor in Critically Unwell Patients: A Narrative Review and a Survey of UK Practice.
    Grauslyte L; Bolding N; Phull M; Jovaisa T
    J Crit Care Med (Targu Mures); 2022 Jul; 8(3):193-203. PubMed ID: 36062042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vasopressor drugs in shock due to myocardial infarction].
    Adamska-Dyniewska H
    Pol Tyg Lek; 1967 Oct; 22(45):1744-7. PubMed ID: 4294154
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.